Bain Capital Life Sciences unveiled Beeline Medicines after licensing five immunology medicines from Bristol Myers Squibb, giving the shelved assets a new development home. Beeline’s pipeline is led by afimetoran, a daily oral candidate for systemic lupus erythematosus; Phase 2 data are expected later this year. The new startup, formed with a $300 million Series A, aims to move assets quickly into late-stage programs, starting with lupus and also progressing candidates aimed at atopic dermatitis and other immune-mediated diseases. Beeline’s leadership includes Saqib Islam, formerly CEO of SpringWorks Therapeutics. For the broader dealmaking ecosystem, the launch demonstrates how large pharma portfolios are being recycled into independently funded vehicles, often with a targeted clinical path and predefined biomarker strategy. It also signals that investors are continuing to underwrite development when pharma-to-biotech handoffs come with meaningful clinical histories. Beeline is expected to report and potentially scale evidence from its lupus program, with subsequent moves dependent on Phase 2 outcomes and the company’s ability to secure supportive regulatory dialogue.